Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olodaterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 17/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olodaterol SCHEMBL29737213 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL140805 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL29355155 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL29371816 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL152331 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL560669 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL561592 | 0.95 | ADRB2 (0.90) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL561364 | 0.94 | ADRB2 (0.89) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL560886 | 0.94 | ADRB2 (0.89) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL4219120 | 0.94 | ADRB2 (0.89) | ADRB2ADRB1CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10059678-B2 | Process for preparing olodaterol and intermediates thereof | REDDY, G. Pratap (IN) | 2018-08-28 | — | — | US | claimed |
| US-20170260149-A1 | A Process for Preparing Olodaterol and Intermediates Thereof | REDDY, G. Pratap (IN) | 2017-09-14 | — | — | US | claimed |
| US-20120034275-A1 | POWDER FORMULATIONS FOR INHALATION, COMPRISING ENANTIOMERICALLY PURE BETA AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | claimed |
| US-8044046-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2011-10-25 | — | — | US | claimed |
| US-20110190284-A1 | AEROSOL FORMULATIONS FOR THE INHALATION OF BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | US | claimed |
| US-7786111-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-08-31 | — | — | US | claimed |
| US-7727984-B2 | R-6-Hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino ]-ethyl}-4H-benzo[1,4]oxazin-3-one, or an acid addition salt thereof; betamimetics; for administration once a day for treating COPD | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2010-06-01 | — | — | US | claimed |
| US-20100009984-A1 | AEROSOL FORMULATIONS FOR THE INHALATION OF BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | claimed |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | claimed |
| US-20090092558-A1 | 6-Hydroxy-8-{1-hydroxy-2-[2-(p-alkoxy- or carboxyalkoxyphenyl)-1,1-dimethylethylamino]ethyl}4H-benzo[1,4]oxazin-3-ones, e.g., 6-hydroxy-8-{1-hydroxy-2-[2-(4-phenoxyacetic acid)-1,1-dimethylethylamino]- ethyl}-4H-benzo[1,4]oxazin-3-one; betamimetics | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-09 | — | — | US | claimed |
| US-7491719-B2 | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-17 | — | — | US | claimed |
| US-20080167298-A1 | MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-07-10 | — | — | US | claimed |
| US-20070155741-A1 | Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-07-05 | — | — | US | claimed |
| WO-2026099100-A1 | DEVICE FOR THE INHALATION-SYNCHRONISED DISPENSING OF A FLUID PRODUCT | APTAR FRANCE SAS (FR) | 2026-05-15 | — | — | WO | disclosed |
| US-20260091018-A1 | COMBINATION PREPARATION CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-04-02 | — | — | US | disclosed |
| US-12533095-B1 | Airway mucus scoring system | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-27 | — | — | US | disclosed |
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| WO-2005111005-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110359-A1 | INHALATION POWDER FORMULATIONS CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050255050-A1 | Powder formulations for inhalation, comprising enantiomerically pure beta agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167298-A1 | MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | ADRB2 28/4885ADRB1 42/4885CHRM2 5/4885 |
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | ADRB1, ADRB2, ADRA1D | ADRB2 2/4885ADRB1 1/4885CHRM2 13/4885 |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | MRGPRX2, MRGPRX1, CFTR | ADRB2 49/4885ADRB1 115/4885CHRM2 13/4885 |
| US-20170260149-A1 | A Process for Preparing Olodaterol and Intermediates Thereof | CYP4A11, CYP11B1, CYP11B2 | ADRB2 47/4885ADRB1 30/4885CHRM2 312/4885 |
| US-20100009984-A1 | AEROSOL FORMULATIONS FOR THE INHALATION OF BETA-AGONISTS | CHRM1, ADRB2, CHRM2 | ADRB2 2/4885ADRB1 6/4885CHRM2 3/4885 |
| US-20110190284-A1 | AEROSOL FORMULATIONS FOR THE INHALATION OF BETA-AGONISTS | CHRM1, ADRB2, CHRM2 | ADRB2 2/4885ADRB1 5/4885CHRM2 3/4885 |
| US-20120034275-A1 | POWDER FORMULATIONS FOR INHALATION, COMPRISING ENANTIOMERICALLY PURE BETA AGONISTS | ADRB1, ADRB2, ADRB3 | ADRB2 2/4885ADRB1 1/4885CHRM2 11/4885 |
| US-20260091018-A1 | COMBINATION PREPARATION CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | HACD3, LIPA, IL2 | ADRB2 2524/4885ADRB1 3250/4885CHRM2 1493/4885 |
| US-20050255050-A1 | Powder formulations for inhalation, comprising enantiomerically pure beta agonists | ADRB1, ADRB2, ADRB3 | ADRB2 2/4885ADRB1 1/4885CHRM2 11/4885 |
| US-10059678-B2 | Process for preparing olodaterol and intermediates thereof | CYP4A11, CYP11B1, CYP11B2 | ADRB2 49/4885ADRB1 30/4885CHRM2 260/4885 |
| US-20090092558-A1 | 6-Hydroxy-8-{1-hydroxy-2-[2-(p-alkoxy- or carboxyalkoxyphenyl)-1,1-dimethylethylamino]ethyl}4H-benzo[1,4]oxazin-3-ones, e.g., 6-hydroxy-8-{1-hydroxy-2-[2-(4-phenoxyacetic acid)-1,1-dimethylethylamino]- ethyl}-4H-benzo[1,4]oxazin-3-one; betamimetics | CHRM1, CHRM2, ADRA2C | ADRB2 6/4885ADRB1 8/4885CHRM2 2/4885 |
| US-12533095-B1 | Airway mucus scoring system | MUC1, IL5, CYSLTR2 | ADRB2 306/4885ADRB1 587/4885CHRM2 61/4885 |
| US-20070155741-A1 | Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | ADRB2 27/4885ADRB1 38/4885CHRM2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.